{
    "clinical_study": {
        "@rank": "6586", 
        "arm_group": [
            {
                "arm_group_label": "senofilcon A - Current Hydration", 
                "arm_group_type": "Active Comparator", 
                "description": "Current Hydration Process"
            }, 
            {
                "arm_group_label": "senofilcon A - Alternate Hydration", 
                "arm_group_type": "Experimental", 
                "description": "Alternate Hydration Process"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the impact of a new contact lens hydration process"
        }, 
        "brief_title": "Clinical Investigation of Senofilcon A Manufactured Using an Alternate Process", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Visual Acuity", 
            "Comfort", 
            "Overall Vision"
        ], 
        "detailed_description": {
            "textblock": "To evaluate the impact on clinical performance of senofilcon A lenses manufactured using an\n      alternate hydration process and compare the performance with senofilcon A lenses\n      manufactured using the current process."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and\n             receive a fully executed copy of the form.\n\n          -  The subject must appear able and willing to adhere to the instructions set forth in\n             this clinical protocol.\n\n          -  The subject must be at least 18 and not more than 70 years of age.\n\n          -  The subject's refractive cylinder must be < 0.75D in each eye.\n\n          -  The subject must have best corrected visual acuity of 20/25 or better in  each eye.\n\n          -  The subject must demonstrate adequate mobility and 20/30 vision OD and OS with the\n             study contact lenses.\n\n          -  The subject must be a habitual and adapted wearer of ACUVUE\u00ae OASYS\u00ae Brand contact\n             lens in both eyes\n\n          -  The subject must have normal eyes (i.e., no ocular medications or infections of any\n             type).\n\n          -  The subject's required spherical contact lens prescription must be in the range of\n             -0.50 to -9.00D in each eye.\n\n        Exclusion Criteria:\n\n          -  Currently pregnant or lactating (subjects who become pregnant during the study will\n             be discontinued).\n\n          -  Any ocular or systemic allergies or diseases that may interfere with contact lens\n             wear.\n\n          -  Any systemic disease, autoimmune disease, or use of medication, that may interfere\n             with contact lens wear.\n\n          -  Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of\n             recurrent corneal erosions, aphakia, or moderate or above corneal distortion by\n             keratometry.\n\n          -  Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy,\n             PRK, LASIK, etc.).\n\n          -  Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization,\n             corneal staining, tarsal abnormalities, conjunctival injection) on the FDA\n             classification scale, any previous history or signs of a contact lens-related corneal\n             inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any\n             other ocular abnormality that may contraindicate contact lens wear.\n\n          -  Any known hypersensitivity or allergic reaction to OPTI-FREE\u00ae PureMoist\u00ae Contact Lens\n             Solution.\n\n          -  Any ocular infection.\n\n          -  Any corneal distortion resulting from previous hard or rigid gas permeable contact\n             lens wear.\n\n          -  Monovision or multi-focal contact lens correction.\n\n          -  Participation in any contact lens or lens care product clinical trial within 14 days\n             prior to study enrollment.\n\n          -  History of binocular vision abnormality or strabismus.\n\n          -  Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious\n             immunosuppressive disease (e.g., HIV, by self report).\n\n          -  Suspicion of or recent history of alcohol or substance abuse.\n\n          -  History of serious mental illness.\n\n          -  History of seizures.\n\n          -  Employee of investigational clinic (e.g., Investigator, Coordinator, Technician)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951703", 
            "org_study_id": "CR-5509"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "senofilcon A - Current Hydration", 
                    "senofilcon A - Alternate Hydration"
                ], 
                "description": "Current Hydration Process", 
                "intervention_name": "senofilcon A - Current Hydration", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "senofilcon A - Current Hydration", 
                    "senofilcon A - Alternate Hydration"
                ], 
                "description": "Alternate Hydration Process", 
                "intervention_name": "senofilcon A - Alternate Hydration", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 3, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32256"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bloomington", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61701"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburg", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66762"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warwick", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02888"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Investigation of Senofilcon A Manufactured Using an Alternate Hydration Process", 
        "overall_official": {
            "affiliation": "Johnson & Johnson Vision Care", 
            "last_name": "Brian Pall, OD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the impact on clinical performance, including comfort, vision, and logMAR visual acuity, of senofilcon A lenses manufactured using an alternate hydration process and compare the performance with senofilcon A lenses manufactured using the current process.", 
            "measure": "Clinical Performance", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 weeks per lens (4 weeks total)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951703"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Vistakon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vistakon", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}